OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
04/16/2026
Back to search
Official data from USPTO
LIGACHEM
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
04/17/2026
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
08/06/2024
Registration date
08/26/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/26/2025
Last transaction
04/17/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
KR
Examiner
SWAIN, MICHELE LYNN
Law office
M70
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of a DNA symbol design in orange, dark grey and light grey, made using two vertically interlocking hexagons followed by the wording "LigaChem". The left side of the upper hexagon is orange and resembles the letter "L" with light grey horizontal lines on the right, and the left side of the bottom hexagon is comprised of light grey horizontal lines with dark grey on the right resembling the reversed letter "C", all followed by the wording LigaChem in stylized black letters. The color white visible through the mark represents background only and is not part of the mark.
Holders and representatives
Holders
LigaChem Biosciences Inc.
Representatives
Richard Y. Kim Snell & Wilmer L.L.P.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Vaccines; food supplements; vitamin preparations; crude medicines for treating canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; nutraceuticals for use as a dietary supplement; biological preparations for medical use for pharmaceutical purposes for the treatment of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; medical pharmaceuticals for use in relation to the treatment of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; chemical preparations for medical use for pharmaceutical purposes for the treatment of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; drug delivery agents consisting of compounds that facilitate delivery of pharmaceuticals for the treatment of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; medical molecular diagnostic reagents for use in relation to the treatment of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; biopharmaceuticals for use in relation to the treatment of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; syrups for pharmaceutical purposes for the treatment of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; medicated lozenges for pharmaceutical purposes; capsules sold empty for pharmaceuticals; chemico-pharmaceutical preparations for pharmaceutical or medical purposesfor canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; drugs for medical purposespharmaceutical preparations for the treatment of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; antibodies for medical purposes; medical antibodiesespecially antibody conjugates and active ingredients and antibody conjugates; chemical reagents for medical useespecially chemical reagents for linking molecules for medical use; pharmaceutical compositions for use in treatment and prevention of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; plant extractsother than essential oilsfor medicinal purposes; pharmaceutical preparations for canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; prescription and non-prescription medicinespillstabletscapsulescapletsliquid dropssachets; pharmaceutical preparations for the treatment and prevention of canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases; antibiotics; anti-cancer preparations; mixed vitamin preparations; chemotherapeutics; pharmaceutical preparations for the treatment of rare canceroncological disordersautoimmune diseasesinflammatory diseasesfibrotic diseases and infectious diseases
Publications
History of USPTO decisions and trademark events.
29 publications found
FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
04/02/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/30/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
03/29/2026
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/15/2026
FIMP
FINAL DISPOSITION PROCESSED
03/15/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/26/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/26/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
08/26/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/10/2025
PUBO
PUBLISHED FOR OPPOSITION
06/10/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/04/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/07/2025
RFNT
REFUSAL PROCESSED BY IB
04/12/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/08/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/08/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/08/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/27/2025
RFRR
REFUSAL PROCESSED BY MPU
03/27/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/21/2025
CNRT
NON-FINAL ACTION WRITTEN
02/20/2025
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
02/19/2025
PBSR
WITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST
02/19/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/14/2025
DOCK
ASSIGNED TO EXAMINER
02/12/2025
MAFR
APPLICATION FILING RECEIPT MAILED
11/12/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/12/2024
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
11/08/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/31/2024
Continuous trademark protection
Get notified about every new filing that threatens LIGACHEM or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.